<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Paclitaxel, one of key drugs to treat a wide range of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, exhibits relative low sensitivity for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was to examine whether and how phosphatidylinositol 3'-kinase (PI3K) signals affect the sensitivity of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to paclitaxel </plain></SENT>
<SENT sid="2" pm="."><plain>Four <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines were exposed to paclitaxel in the presence of PI3K signal inhibitors, such as LY294002, siRNA for Akt, or <z:chebi fb="0" ids="9168">rapamycin</z:chebi>, with or without MAPK inhibitor, PD98059 </plain></SENT>
<SENT sid="3" pm="."><plain>Cell viability and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were determined by <z:chebi fb="0" ids="53233">MTT</z:chebi> assay, cell cycle analysis in flow cytometer and Hoechst nuclear staining </plain></SENT>
<SENT sid="4" pm="."><plain>To analyze the PI3K activity, the expression in phosphorylated Akt and downstream effectors of p70S6 kinase (S6K) were evaluated by Western blot analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Paclitaxel alone (5-10 nM) did not induce the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> four cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>Although LY294002 alone did not affect the cell viability, it suppressed the Akt and S6K activities and induced the sub-G1 arrest/<z:mpath ids='MPATH_3'>apoptosis</z:mpath> when paclitaxel was co-administered, as well as the Akt siRNA and <z:chebi fb="0" ids="9168">rapamycin</z:chebi> did </plain></SENT>
<SENT sid="7" pm="."><plain>Simultaneous blockade of PI3K and MAPK pathways more suppressed the S6K activity and further increased the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, PI3K is involved in low susceptibility of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to paclitaxel and dual PI3K/MAPK targeting agents may evolve a new paclitaxel-based chemotherapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>